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Finding ways to increase the biosynthesis of medically important microbial secondary metabolites is a chal-
lenge of microbial chemical biology. Lechner et al. (in this issue of Chemistry & Biology) show that transcrip-
tional regulation can be manipulated to selectively increase the production of a desired metabolite.Without actinomycetes, medicine would
not be what it is today. As a part of their
‘‘secondary’’ or nonessential metabolism
actinomycetes produce small molecules
that have an extraordinary range of bio-
logical activities. These metabolites are
used as anticancer agents, immune
suppressants, and most famously, as
antibiotics. The majority of secondary
metabolites are polyketides, nonriboso-
mally derived peptides, or combinations
thereof. Their biosynthetic pathways
often require dozens of enzymes and are
encoded in discrete genomic islands.
The genes for the core synthases can
be easily identified by sequence ho-
mology. Genome sequencing has re-
vealed that actinomycete genomes
encode many more secondary metabo-
lites than originally anticipated based
on prior screening efforts—some harbor
close to 40 distinct clusters (Nett et al.,
2009). In the laboratory, many of these
molecules are produced at very low
levels and finding ways to activate their
synthesis is an important area of ongoing
research.
Most secondary metabolite biosyn-
thetic gene clusters encode regulatory
proteins that control the transcription of
the biosynthetic and/or self-resistance
genes. Their regulation can be very
complex: the biosynthetic gene cluster
for pristinamycin IA and IIA for example,
a massive brute weighing in at 210 kbp,
encodes seven DNA binding transcription
factors (Mast et al., 2011). In addition to
pathway specific regulators, pleiotropi-
cally acting regulators, typically encoded
outside biosynthetic clusters, control
multiple metabolites. It is likely that a
regulatory network consisting of both
pleiotropic and pathway-specific regula-
tors explains the feeble production of somany secondary metabolites under labo-
ratory conditions.
Manipulating the regulation of second-
ary metabolism is an attractive means of
enhancing the yields of poorly expressed
molecules. Overexpressing pathway-
specific regulators has been used to
enhance yields of known molecules
(Stutzman-Engwall et al., 1992) and to
activate ‘‘silent’’ gene clusters and iden-
tify new molecules (Laureti et al., 2011).
Secondary metabolite yields have also
been enhanced through the expression
of pleiotropic regulators (McKenzie et al.,
2010). Technologies that take advantage
of regulatory mechanisms can comple-
ment other strategies that have been
developed for small molecule discovery
(Gomez-Escribano and Bibb, 2011;
Hosaka et al., 2009; Komatsu et al., 2010).
Lechner et al. (2011 [in this issue of
Chemistry & Biology]) report a new twist
on the use of regulatory genes to manipu-
late secondary metabolism—the use of
a pathway-specific regulator to manipu-
late the structure of a secondary metabo-
lite. Many biosynthetic pathways produce
mixtures of related molecules rather than
a single species. These analogs can
have different biochemical activities but
their shared chemical properties can
make purification of individual species
a substantial challenge. Salinosporamide
A is a covalent inhibitor of the 20S protea-
some that is in clinical trials for cancer
therapy. It is a chlorinated molecule
produced by the actinomycete Salinis-
pora tropica along with several related
but unchlorinated molecules (Figure 1).
Chlorination is required for covalent
inhibition of the 20S proteasome by
salinosporamide A and nonhalogenated
derivatives are not clinically useful as pro-
teasome inhibitors. Biosynthesis of sali-Chemistry & Biology 18, December 23, 2011 ªnosporamide A requires the precursor
chloroethylmalonyl-CoA, produced by a
subpathway of eight enzymes encoded
in the sal gene cluster (Eusta´quio et al.,
2009). It is this precursor that ensures
chlorination of the final biosynthetic pro-
duct. In contrast, other salinosporamide
derivatives are synthesized from precur-
sors drawn directly from primary metabo-
lism (Figure 1).
The sal biosynthetic gene cluster
encodes three putative transcription
factors including the LuxR-like protein
SalR2. Lechner and colleagues show
that SalR2 binds and activates the
promoters of salL, salM, and salN in addi-
tion to exerting an autoregulatory effect
on its own promoter. SalL, SalM, and
SalN are required for three of the earliest
steps in chloroethylmalonyl-CoA biosyn-
thesis. Deletion of salR2 eliminates the
biosynthesis of chloroethylmalonyl-CoA
and hence salinosporamide A, but has
no impact on nonhalogenated salino-
sporamide derivatives. By placing salR2
under the control of a constitutive pro-
moter, the authors were able to double
the yields of salinosporamide A without
affecting production of other nonhaloge-
nated species. Most pathway specific
activators are thought to regulate entire
biosynthetic pathways rather than pre-
cursor subpathways. The data presented
by Lechner et al. (2011) clearly shows
that subpathways can be regulated inde-
pendently of the core synthase genes.
SalR2 is an atypical response regulator
lacking the conserved residues required
for phosphorylation. How the expression
and activity of atypical response regula-
tors like SalR2 are regulated remains an
open question. It has been suggested
that the activities of similar transcription
factors are regulated by the final products2011 Elsevier Ltd All rights reserved 1515
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Figure 1. SalR2 Regulates a Precursor Subpathway Required for Salinosporamide A Biosynthesis
The precursors required for the biosynthesis of other salinosporamide derivatives are derived directly from primary metabolism.
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they are encoded. However, very high
concentrations of small molecule were
required to achieve this biochemical
effect and it is unclear whether this is bio-
logical significant or widespread (Wang
et al., 2009). If correct, however, it could
be consistent with an additional layer in
the biosynthetic regulation of salinospor-
amides and other secondary metabolites
and could be utilized to further manipulate
secondary metabolite production by pre-
venting feedback inhibition.
The Salinispora are not widely studied
and the biotechnological resources avail-
able for their genetic manipulation are
limited. Lechner et al. (2011) have adapt-
ed a promoter for use in S. tropica, which
has broad implications in other related
organisms. Marine actinomycetes like
Salinispora are recognized for their
production of novel secondary metabo-
lites (Imhoff et al., 2011) and genetic tools
like the ones developed here will be
crucial for further study of the biosyn-
thesis and regulation of secondary
metabolism in these organisms.
The work presented by Lechner et al.
(2011) illuminates another example of the
complex regulatory backdrop to sec-
ondary metabolism and underscores1516 Chemistry & Biology 18, December 23,how much there is yet to learn. Although
polyketide and nonribosomal peptide
production are fairly well understood in
biochemical terms, we know surprisingly
little about how and why their expression
and biosynthesis are regulated. We do
not understand how secondary metabo-
lism is integrated into primary metabo-
lism, if there is a preferable order to the
expression of biosynthetic enzymes,
whether these enzymes assemble into
multiprotein complexes or how biosyn-
thetic and self-resistance proteins
interact. Indeed, our understanding of
why actinomycetes synthesize such
a large array of secondary metabolites is
limited. Knowledge of the regulatory
mechanisms governing secondary
metabolite biosynthesis and resistance
could yield new ideas for enhancing
synthesis, manipulating the structures of
known molecules, and for discovering
new ones.REFERENCES
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